Double unrelated reduced-intensity umbilical cord blood transplantation in adults
- PMID: 17222756
- PMCID: PMC2947324
- DOI: 10.1016/j.bbmt.2006.08.041
Double unrelated reduced-intensity umbilical cord blood transplantation in adults
Abstract
Umbilical cord blood (UBC) stem cells are a useful stem cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated with high transplantation-related mortality (TRM). In most cases, mortality is due to infection related to slow engraftment and immunoincompetence. In this study, we used a reduced-intensity conditioning regimen of fludarabine, melphalan, and antithymocyte globulin followed by 2 partially matched UBC units. The UBC units were a 4/6 HLA match or better with each other and with the patient and achieved a minimum precryopreservation cell dose of 3.7 x 10(7) nucleated cells/kg. A total of 21 patients (median age, 49 years) were treated. The median time to an absolute neutrophil count > 0.5 x 10(9)/L was 20 days, and the median time to an unsupported platelet count > 20 x 10(9)/L was 41 days. Two patients experienced primary graft failure and underwent a second UBC transplantation. One patient had a late graft failure. Acute graft-versus-host disease (GVHD) grade II-IV occurred in 40% of patients. The 100-day TRM was 14%, and the 1-year disease-free survival was 67%. Mixed chimerism was associated with a higher risk of chronic GVHD. Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen.
Figures
Similar articles
-
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7. Biol Blood Marrow Transplant. 2013. PMID: 23664940
-
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.Blood. 2002 Dec 1;100(12):3919-24. doi: 10.1182/blood-2002-04-1150. Epub 2002 Aug 8. Blood. 2002. PMID: 12393448 Clinical Trial.
-
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.Lancet. 2014 Feb 1;383(9915):436-48. doi: 10.1016/S0140-6736(13)62069-3. Epub 2013 Oct 23. Lancet. 2014. PMID: 24161820 Clinical Trial.
-
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.Biol Blood Marrow Transplant. 2005 Aug;11(8):637-46. doi: 10.1016/j.bbmt.2005.05.003. Biol Blood Marrow Transplant. 2005. PMID: 16041314 Clinical Trial.
-
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.Leuk Lymphoma. 2012 May;53(5):901-6. doi: 10.3109/10428194.2011.631159. Epub 2012 Jan 3. Leuk Lymphoma. 2012. PMID: 21988645 Free PMC article. Clinical Trial.
Cited by
-
Umbilical Cord Blood Banking for Transplantation in Morocco: Problems and opportunities.J Stem Cells Regen Med. 2014 Nov 28;10(2):28-37. doi: 10.46582/jsrm.1002006. eCollection 2014. J Stem Cells Regen Med. 2014. PMID: 25705096 Free PMC article. Review.
-
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.Blood. 2010 Nov 25;116(22):4693-9. doi: 10.1182/blood-2010-05-285304. Epub 2010 Aug 4. Blood. 2010. PMID: 20686119 Free PMC article.
-
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.Blood. 2009 Nov 5;114(19):4293-9. doi: 10.1182/blood-2009-05-220525. Epub 2009 Aug 25. Blood. 2009. PMID: 19706886 Free PMC article. Clinical Trial.
-
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.Blood. 2011 Mar 24;117(12):3277-85; quiz 3478. doi: 10.1182/blood-2010-08-300491. Epub 2010 Dec 13. Blood. 2011. PMID: 21149633 Free PMC article. Clinical Trial.
-
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.Transfusion. 2009 May;49(5):995-1002. doi: 10.1111/j.1537-2995.2008.02077.x. Epub 2009 Jan 21. Transfusion. 2009. PMID: 19159415 Free PMC article. Clinical Trial.
References
-
- Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157–166. - PubMed
-
- Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–1618. - PubMed
-
- Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood. 2003;102:4290–4297. - PubMed
-
- Ballen KK. New trends in umbilical cord blood transplantation. Blood. 2005;105:3786–3792. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials